Ascletis In-Licenses China Rights to Second Hepatitis C Drug

Ascletis, a China-US novel drug developer, in-licensed China rights to a clinical-stage hepatitis C treatment from Presidio of San Francisco. PPI-668 is an NS5A inhibitor currently in a Phase II trial in the US. Ascletis is also developing another treatment for HCV: a Roche protease inhibitor known as danoprevir. Ascletis thinks the two drugs can be combined to combat HCV in an interferon-free regimen. More details.... Stock Symbol: (VIX: ROG) Share this with colleagues: // //